Awareness of Pleiotropic and Cardioprotective Effect of Statins in Patients with Coronary Artery Disease

Table 1

Demographic, echocardiographic, and clinical features of coronary artery disease patients according to statin use.

	Drug-Free Group; n=217	Moderate-Intensity Statin Group; n=130	High- Intensity Dose Statin Group; n=157	p
Age, year	62.1 ± 9.8	63.7 ± 8.9	62.5 ± 9.4	0.32
Gender, male  (n,%)	148, %40.1	99, %26.8	122, %33.1	0.08
DM, present  (n,%)	85, %49.4	40, %23.3	47, %27.3	0.11
HT, present  (n,%)	127, %41.8	85, %28	92, %30.3	0.39
Creatinine, mg/dl	0.88 0.74-1.0	0.9 0.79-1.0	0.89 0.79-1.0	0.18
AST, U/L	20 16.5-24	21 17.7-24	24 19-32	<0.001
LDL Cholesterol, mg/dL	126.6 ± 26.3	97.2 ± 26.9	78.7 ± 28.1	<0.001
Active Smoking, (n,%)	64, %55.2	20, %17.2	32, %27.6	0.007
Heart Failure, present  (n,%)	40, %38.5	31, %29.8	33, %31.7	0.47
	Drug-Free Group; n=217	Moderate and High Intensity Statin Group; n=287		p
Literacy, (n,%)	187 (%86.1)	278 (%96.8)		<0.001
Alcohol consumption, (n,%)	25 (%11.5)	8 (%2.7)		<0.001
LDL Cholesterol < 70 mg/dL	1 (%0.4)	93 (%32.4)		<0.001

DM; diabetes mellitus, HT; hypertension, AST; aspartate aminotransferase, LDL;low density lipoprotein.
=x² value; <0.05 versus drug free group; <0.05 versus low dose statin group; =Fisher’s extract test.
Values are expressed as mean ± standard deviation or median (1st–3rd quartiles), as appropriate.
p value below 0.05 was considered significant and significant parameters were shown by bold type.